Sernova Corp T.SVA

Sernova to present at Rodman & Renshaw conference

[Sonny7]

=======================================================================
Re: News Releases - Wednesday, September 04, 2013
Sernova to Present at 15th Annual Rodman & Renshaw Global
Investment Conference
=======================================================================

LONDON, ONTARIO (Marketwire -- Sept. 4, 2013) - Sernova Corp. (TSX-V:
SVA), today announced that Dr. Philip Toleikis, Sernova's President and
CEO, will present at the 15th Annual Rodman & Renshaw Global Investment
Conference, sponsored by H.C. Wainwright & Co., LLC, at 12:30 p.m. EDT,
Tuesday, Sept. 10, in room 7.03 at the Millennium Broadway Hotel in
New York City.

Dr. Toleikis will provide an overview of the company's business
strategy and the ongoing Phase I/II clinical study of the Cell
Pouch(TM) with insulin producing islets in patients with Type-1
diabetes.

If you are an institutional investor and interested in attending
Sernova's presentation, please click on the following link
(www.rodm.com) to register for the Rodman & Renshaw conference. Once
your registration is confirmed, you will be prompted to log into the
conference website to request a one-on-one meeting with Dr. Toleikis.

About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable medical device which has
been contract manufactured (ISO13485). It is placed under the skin, and
forms an ideal environment rich in microvessels and tissue matrix for
the placement and function of therapeutic cells. The Cell Pouch(TM) is
currently being evaluated in clinical trials at the University of
Alberta with Dr. James Shapiro as principal investigator in patients
with Type-1 diabetes receiving an islet transplant.

About Sernova

Sernova Corp is a clinical stage company developing medical
technologies for the treatment of chronic debilitating metabolic
diseases including diabetes, blood disorders such as hemophilia and
other diseases to replace proteins or hormones in short supply in the
body. Sernova is developing the Cell Pouch(TM), an implantable medical
device which when placed under the skin forms an environment rich in
tissue matrix and microvessels, ideal for placing therapeutic cells
which then release proteins and/or hormones as required. The
therapeutic cells are provided an immune-protected environment by
Sernova's proprietary technology Sertolin(TM).

For further information contact:
Philip Toleikis, Ph.D., President and CEO
Tel: [phone]
[e-mail]
www.sernova.com

Tony Russo, Ph.D.
Russo Partners, LLC
Tel: [phone]
[e-mail]